Overview
Investors searching JTRSY vs INJ usually want a clear market-cap and momentum snapshot. JTRSY prints $1,887.28 (+0.00%) while Injective is at $5.10 (+3.59%), with volume edge currently on Injective.
Quick winners
Full comparison
| Metric | JTRSY | INJ |
|---|---|---|
| Price | $1,887.28 | $5.10 |
| Market Cap | $871.05M | $490.41M |
| FDV | — | — |
| Volume 24h | $0.000000 | $2.58M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 73.00 | 99.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +3.64% | +5.97% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | JTRSY | INJ |
|---|---|---|
| 1H | — | — |
| 24H | +0.00% | +3.59% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | JTRSY | INJ |
|---|---|---|
| RSI | 49.02 | 49.29 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 67.35 | 0.29 |
| ADX | 21.33 | 12.19 |
| Support | 1,827.82 | 4.91 |
| Resistance | 1,960.30 | 5.47 |
| Trend | bearish | neutral |
| Momentum | 59.00 | — |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, JTRSY shows RSI 49.02 with trend bias bearish, while Injective sits at RSI 49.29 (neutral). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | JTRSY | INJ |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | — | 0.00 |
| Github activity | — | 118.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
JTRSY
Injective
Pros and cons
Pros of JTRSY
- JTRSY typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Market-cap scale on JTRSY may dampen some idiosyncratic shocks versus smaller peers.
- JTRSY has an established coin page footprint on PEPS for continuous monitoring.
- JTRSY often anchors narratives that attract sustained media and analyst coverage.
Cons of JTRSY
- Indicator stacks on JTRSY may stay stretched longer than expected in strong trends.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- When dominance narratives fade, JTRSY can lag hotter rotation names.
- Crowded positioning around JTRSY sometimes amplifies squeeze or flush risk.
Pros of Injective
- If technical momentum aligns, Injective may outperform on medium-term windows.
- Injective can offer higher relative beta when market attention rotates toward its niche.
- Diversifying versus JTRSY with Injective can change portfolio factor exposure.
Cons of Injective
- Higher volatility on INJ cuts both ways and demands stricter risk limits.
- Relative underperformance versus JTRSY can persist through entire market regimes.
- Smaller book depth versus large caps can increase slippage for Injective.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to JTRSY, while short-term performance leans toward Injective. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
PEPS synthesizes module output into a readable pair brief. Headline stats put JTRSY at $1,887.28 and Injective at $5.10. Relative performance over 24h (Injective) is a short window. Pair it with 30d/1y rows before inferring regime change. Return to related comparisons and individual coin intelligence pages to validate whether the relative story still holds after fresh prints.
FAQ
Which is better, JTRSY or Injective?
“Better” depends on horizon and risk. JTRSY leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, JTRSY or INJ?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both JTRSY and Injective.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.